Cargando…
Discussion of tumor mutation burden as an indicator to predict efficacy of immune checkpoint inhibitors: A case report
There are many treatment options for advanced lung cancer, among which immunotherapy has developed rapidly and benefited a lot of patients. However, immunotherapy can only benefit a subgroup of patients, and how to select patients suitable for this therapy is critical. Tumor mutation burden (TMB) is...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381827/ https://www.ncbi.nlm.nih.gov/pubmed/35992799 http://dx.doi.org/10.3389/fonc.2022.939022 |